Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

1. Radient Pharmaceuticals ( RPC)

Company Profile: Radient Pharmaceuticals produces and sells diagnostic tests to monitor and detect types of cancer. Last month, TheStreet's Adam Feuerstein reported that Radient missed a loan payment of $843,750 in May, putting the company in default.

Altman Z-score: -629.33

Current Share Price: 20 cents (June 7)

2011 Return: -80%

Current Ratio: 0.01, indicating that Radient would have major difficulties covering its short-term liabilities with its current assets.

>>To see these stocks in action, visit the Stocks Under $5 at Risk of Bankruptcy portfolio on Stockpickr.

-- Written by Robert Holmes in Boston.

>To contact the writer of this article, click here: Robert Holmes.

>To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet.

>To submit a news tip, send an email to: tips@thestreet.com.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

A Busy Week for Six Biotech Stocks

A Busy Week for Six Biotech Stocks

Radient Outlook on India Partner Dims

Radient Pharma Defaults on Loan

Radient Pharma Defaults on Loan

Biotech Stock Mailbag: Neoprobe

Biotech Stock Mailbag: Neoprobe